Table 1 COVID-19 seroprevalence during the study period
|  | Overall (N = 4496) n (%) | 95% CI | Non-hybrid (N = 3506) n (%) | 95% CI | Hybrid (N = 990) n (%) | 95% CI | |
|---|---|---|---|---|---|---|---|
Dec. 2022 | Anti-S | 4400 (97.9%) | 97.4%, 98.3% | 3410 (97.3%) | 96.7%, 97.8% | 990 (100.0%) | 99.6%, 100.0% |
| Â | Anti-N | 1039 (23.1%) | 21.9%, 24.4% | 73 (2.1%) | 1.6%, 2.6% | 966 (97.6%) | 96.4%, 98.4% |
Feb. 2023 | Anti-S | 4416 (98.2%) | 97.8%, 98.6% | 3426 (97.7%) | 97.2%, 98.2% | 990 (100.0%) | 99.6%, 100.0% |
| Â | Anti-N | 1358 (30.2%) | 28.9%, 31.6% | 413 (11.8%) | 10.7%, 12.9% | 945 (95.5%) | 94.0%, 96.7% |
